Dr. Reddy’s Laboratories Ltd. ADR (RDY) concluded trading on Thursday at a closing price of $14.83, with 2.57 million shares of worth about $38.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -5.78% during that period and on January 16, 2025 the price saw a loss of about -3.20%. Currently the company’s common shares owned by public are about 834.38M shares, out of which, 833.03M shares are available for trading.
Stock saw a price change of -6.20% in past 5 days and over the past one month there was a price change of 2.56%. Year-to-date (YTD), RDY shares are showing a performance of -6.08% which increased to 7.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.43 but also hit the highest price of $16.89 during that period. The average intraday trading volume for Dr. Reddy’s Laboratories Ltd. ADR shares is 1.31 million. The stock is currently trading -3.63% below its 20-day simple moving average (SMA20), while that difference is down -0.01% for SMA50 and it goes to -2.23% lower than SMA200.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) currently have 834.38M outstanding shares and institutions hold larger chunk of about 14.47% of that.
The stock has a current market capitalization of $12.35B and its 3Y-monthly beta is at 0.51. PE ratio of stock for trailing 12 months is 19.34, while it has posted earnings per share of $0.77 in the same period. Its PEG reads 26.23 and has Quick Ratio of 1.36 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RDY, volatility over the week remained 1.58% while standing at 1.40% over the month.
Stock’s fiscal year EPS is expected to rise by 1.21% while it is estimated to increase by 0.42% in next year. EPS is likely to shrink at an annualized rate of 0.74% for next 5-years, compared to annual growth of 20.07% made by the stock over the past 5-years.
Stock get a Buy rating from BofA Securities on March 17, 2023.
